
Iovance Biotherapeutics IOVA
$ 3.77
-1.44%
Annual report 2025
added 02-24-2026
Iovance Biotherapeutics Interest Expense 2011-2026 | IOVA
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 200 K | -5.66 K | 445 K | 1.92 M | 152 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.92 M | -5.66 K | 543 K |
Quarterly Interest Expense Iovance Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 221 K | 164 K | 126 K | - | 8 K | 73 K | - | - | -4.19 K | - | - | - | - | 104 K | 342 K | - | 127 K | 111 K | 88.5 K | - | 31.6 K | -399 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 342 K | -399 K | 76.4 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.88 | 3.89 % | $ 9.34 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 323.46 | -2.98 % | $ 42.4 B | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Cabaletta Bio
CABA
|
2 M | $ 3.55 | 4.26 % | $ 357 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Aligos Therapeutics
ALGS
|
2.2 M | $ 8.1 | 9.16 % | $ 80.1 M | ||
|
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | ||
|
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 21.91 | 1.04 % | $ 1.02 B | ||
|
CymaBay Therapeutics
CBAY
|
18.9 M | - | - | $ 3.45 B | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 101.31 | 1.85 % | $ 27.2 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 3.07 | -3.15 % | $ 5.05 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Galectin Therapeutics
GALT
|
1.03 M | $ 2.3 | -10.35 % | $ 147 M | ||
|
ContraFect Corporation
CFRX
|
-4.81 M | - | -5.16 % | $ 5.39 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
58 K | $ 1.39 | -10.32 % | $ 357 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.21 | -0.71 % | $ 450 M | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 23.86 | -2.93 % | $ 3.04 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.54 | 3.02 % | $ 410 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | ||
|
Incyte Corporation
INCY
|
25.1 M | $ 95.06 | -2.11 % | $ 18.6 B | ||
|
Caladrius Biosciences
CLBS
|
-257 K | - | -16.75 % | $ 25.8 M |